September 2, 2020
A Rhode Island federal judge has given the final green light to deals totaling about $183.5 million to settle allegations that Lupin and a pair of Allergan units worked to sideline generic alternatives of the birth control drug Loestrin.
On Tuesday, U.S. District Judge William E. Smith granted final approval to a trio of settlements in sprawling litigation that has involved Lupin Pharmaceuticals and Allergan subsidiaries Warner Chilcott and Watson Pharmaceuticals.
Specifically, the judge approved a $1 million settlement between Lupin and a group of end payors of the drug, a $62.5 million deal between third-party payors and the Warner Chilcott defendants, and a $120 million settlement between Warner Chilcott and Watson and a group of direct drug buyers.
. . .
The end-payors and third-party payors are represented by Motley Rice LLC, Miller Law LLC, Hilliard & Shadowen LLP and Cohen Milstein Sellers & Toll PLLC.
Read $184M Settlements OK’d in Loestrin Buyers’ Antitrust Row.